Menopausal Status at Diagnosis is a Prognostic Indicator in Patients who are Operated for Uterine Carcinosarcoma
Abstract
Objectives: Uterine carcinosarcoma is a rare type of uterine cancer, and due to its rarity, there is limited evidence for prognostic factors and treatment. The objective of this study is to assess the influence of histologic, clinical, and demographic characteristics on overall survival (OS) and recurrence-free survival (RFS).
Materials and Methods: Patients who had diagnosis of uterine carcinosarcoma and followed by the medical oncology department of three hospitals from Türkiye between January 2013 and January 2023 were retrospectively evaluated. All patients had local disease and were surgically managed, and patients were excluded if they did not have primary surgical management.
Results: The study included 62 women who were primarily treated with surgery and had a median age of 64.5 (interquartile range=14) years. Recurrence was observed in 26 patients (41.9%), with a median RFS of 11.63 months [95% confidence interval (CI): 1.99-21.26]. A shorter RFS was observed in patients with myometrial invasion [hazard ratio (HR) 2.48, 95% CI 1.04-5.93, p=0.04], while postmenopausal diagnosis was a predictor for longer RFS (HR 0.02, 95% CI 0.004-0.14, p<0.001). The median OS was 43.17 months. Postmenopausal diagnosis was associated with prolonged OS (HR 0.003, 95% CI 0-0.45, p<0.001).
Conclusion: The results of our study show that being diagnosed before menopause is linked to a shorter RFS and OS in women with uterine carcinosarcoma who had surgery to treat local disease
Keywords
Uterine carcinosarcoma, prognostic factor, menopausal status
Ethical Statement
Ethics Committee Approval: This study has been approved by the Ankara University Faculty of Medicine Human Research Ethics Committee (approval no.: İ06-385-23, date: 16.06.2023).
Informed Consent: This is as a retrospective observational study.
Footnotes Authorship Contributions
Concept: H.B., E.B.K., Design: H.B., E.B.K., Data Collection and/or Processing: H.B., M.Y., S.S., F.Y., O.A., D.U., O.Y., Analysis and/or Interpretation: H.B., M.Y., Literature Search: H.B., E.B.K., Writing: H.B., D.U., O.Y., E.B.K.
Conflict of Interest: There is no potential conflict of interest to declare.
Financial Disclosure: This study received no financial support.
References
- 1. Pezzicoli G, Moscaritolo F, Silvestris E, et al. Uterine carcinosarcoma: an overview. Critical Rev Oncol/Hematol. 2021;163:103369.
- 2. El-Nashar SA, Mariani A. Uterine carcinosarcoma. Clin Obstet Gynecol. 2011;54:292-304.
- 3. Leath CA 3rd Numnum TM, Kendrick JE 4th, et al. Patterns of failure for conservatively managed surgical stage I uterine carcinosarcoma: implications for adjuvant therapy. Int J Gynecol Cancer. 2009;19:888-891.
- 4. Sartori E, Bazzurini L, Gadducci A, et al. Carcinosarcoma of the uterus: a clinicopathological multicenter CTF study. Gynecologic Oncology. 1997;67:70-75.
- 5. Major FJ, Blessing JA, Silverberg SG, et al. Prognostic factors in earlystage uterine sarcoma: a Gynecologic Oncology Group Study. Cancer. 1993;71:1702-1709.
- 6. Matsuzaki S, Klar M, Matsuzaki S, Roman LD, Sood AK, Matsuo K. Uterine carcinosarcoma: contemporary clinical summary, molecular updates, and future research opportunity. Gynecol Oncol. 2021;160:586-601.
- 7. Raffone A, Travaglino A, Raimondo D, et al. Uterine carcinosarcoma vs endometrial serous and clear cell carcinoma: a systematic review and metaanalysis of survival. Int J Gynecol Obstet. 2022;158:520-527.
- 8. Toboni MD, Crane EK, Brown J, Shushkevich A, et al. Uterine carcinosarcomas: from pathology to practice. Gynecol Oncol. 2021;162:235-241.
- 9. Gonzalez Bosquet J, Terstriep SA, Cliby WA, et al. The impact of multimodal therapy on survival for uterine carcinosarcomas. Gynecol Oncol. 2010;116:419-423.
- 10. Bogani G, Ray-Coquard I, Concin N, et al. Endometrial carcinosarcoma. Int J Gynecol Cancer. 2023;33:147-174.